What happened with ANL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Adlai Nortye Ltd., now renamed Adlai Nortye Group Ltd., develops cancer treatments, focusing on drugs targeting RAS proteins and next-generation cancer immunotherapies. Its candidates remain in preclinical studies or clinical trials. None is approved for sale, and the company has no product-sales revenue.
Drug-development partners pay for rights to its candidates. ASK Pharm has exclusive rights to develop, manufacture and sell AN9025 in mainland China, Hong Kong and Macao, while Adlai Nortye retains rights elsewhere. The agreement provides for upfront fees, payments when development or sales milestones are reached, and royalties on future sales. Biotime has paid for transferred rights to AN4005, AN3025 and other early-stage programs, with further payments linked to development and sales. These arrangements provide income before Adlai Nortye can sell drugs itself, but future payments depend on the programs advancing.
The business depends on clinical results, regulatory approvals and continued funding. Adlai Nortye relies on outside firms to support trials and manufacture drug supplies, and has financed its activities mainly through equity and debt rather than product sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Adlai Nortye’s results hinge on clinical progress and licensing payments, including its AN9025 partnership with ASK Pharm, which holds commercialization rights in Greater China excluding Taiwan.
Revolution Medicines directly challenges Adlai Nortye’s AN9025 with drugs that block active RAS in cancers dependent on it; both companies are developing treatments rather than reporting sales from these candidates. Watch clinical progress for its broad RAS inhibitor daraxonrasib as a competing approach to AN9025.
Erasca is pursuing the same RAS-driven cancer market as Adlai Nortye’s AN9025, with neither company reporting sales from these candidates. Clinical results for Erasca’s pan-RAS drug ERAS-0015 and pan-KRAS drug ERAS-4001 are worth watching for the competing treatments AN9025 may face.
BridgeBio Oncology Therapeutics is developing drugs for RAS-driven cancers that directly overlap with Adlai Nortye’s RAS-targeting pipeline, rather than selling approved treatments. Its progress in developing inhibitors for use together in KRAS-mutant tumors is a competitive development to watch alongside Adlai Nortye’s AN9025.
BlossomHill Therapeutics’ BH-501284 competes for the broad RAS-inhibitor opportunity pursued by Adlai Nortye’s AN9025, but this pan-KRAS cancer drug is still preclinical while AN9025 is in Phase I. Watch BH-501284’s development progress, not product sales: BlossomHill has no history of commercializing medicines.
Tempest Therapeutics offers a competing way to block EP4 in cancer: its TPST-1495 blocks both EP2 and EP4, while Adlai Nortye’s AN0025 blocks EP4 alone. Watch TPST-1495’s clinical data alongside AN0025’s development with radiotherapy or chemoradiotherapy for rectal cancer; Tempest would seek a commercialization partner if its candidates are approved.
Silexion Therapeutics targets cancer biology that overlaps with Adlai Nortye’s broad RAS inhibitors, but its SIL204 aims to stop mutated KRAS protein from being made using gene-silencing RNA, rather than blocking the protein itself. Watch its development for unresectable, locally advanced pancreatic cancer with KRAS G12D/V mutations; SIL204 is not yet a commercial product.
Fed Interest Rate Decision
Adlai Nortye’s Fed-rate exposure comes through its bank borrowings and potential need for new financing: higher U.S. rates can make debt more costly, while lower rates can ease that cost.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could raise the cost of Adlai Nortye’s debt that reprices and make new borrowing less favorable, increasing the funding burden on its drug-development work.
If it comes in below expectations
Lower rates could ease the cost of debt that reprices and make new borrowing more favorable, reducing financing pressure as Adlai Nortye funds drug development.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report will show how daraxonrasib, its broad RAS inhibitor, is progressing clinically and what that means for the competition facing Adlai Nortye’s AN9025.
Look for whether daraxonrasib is advancing clinically and whether the evidence reported supports further development. Clear progress with persuasive evidence would show that another approach for cancers dependent on RAS is moving forward, making the competition for AN9025 more concrete. Limited progress or inconclusive evidence would mean that this competing approach remains less established, not that AN9025 is more effective.
Tempest Therapeutics, Inc. earningsTPST
Tempest Therapeutics’ report will show how its drug TPST-1495, which blocks both EP2 and EP4, is progressing and how that approach compares with Adlai Nortye’s EP4-blocking AN0025.
Look at TPST-1495’s clinical progress and the evidence reported. It blocks both EP2 and EP4, while AN0025 blocks EP4 alone and is being developed with radiotherapy or chemoradiotherapy for rectal cancer. Clear progress with persuasive evidence would give the dual-blocking approach more weight as a competitor; limited progress or inconclusive evidence would leave it less established, but would not prove AN0025 is more effective.
